CNN

AB Science announces that the European Academy of Allergy & Clinical Immunology (EAACI) 2020 Annual Congress has accepted its phase 3 study results with masitinib in severe ...

The European Academy of Allergy & Clinical Immunology (EAACI) 2020 Annual Congress has accepted AB Science phase 3 study AB07015 results with masitinib in severe asthma to be delivered as a late ...
Business Insider

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM NEUROFILAMENT LIGHT ...
Business Insider

AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors

AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF CANINE MAST CELL TUMORS AB SCIENCE PRESENTS PERSPECTIVE OF THE ANIMAL ...
Yahoo Finance

AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS

AB Science SA (Euronext - FR0010557264 - AB) announced the identification of a potential biomarker for assessing the activity of masitinib in pathological microglial involvement in Amyotrophic Lateral ...
Hosted on MSN

Ab Science’s Phase 3 ALS Trial: A Key Development for Investors

Ab Science ((ABSCF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
CNN

Letter to AB Science stakeholders on COVID-19 pandemic impact on AB Science clinical studies

At this time, we expect that the COVID-19 pandemic will have limited impact on our clinical development program, as this crisis struck at a time when most of our on-going clinical studies were ...
Seeking Alpha

AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALS

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in ...
Business Wire

Skuldtech and AB Science announce the identification of new predictive markers for pancreatic cancer survival associated with masitinib treatment

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Skuldtech, a genomic and pharmacogenomic company specialized in developing diagnostic tests, and AB Science (NYSE Euronext – FR0010557264 – AB), ...
Morningstar

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection

While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are ...
WKRN-TV

AB Science today reports its revenues for the first half of 2023 and provides an update on its activities

AB Science announced in March 2023 a case report from the initial stage of its Phase I/II study (AB18001) evaluating AB8939, a microtubule destabilizer, in patients with refractory and relapsed acute ...